Induction of retinoid X receptor activity and consequent upregulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells

Cancer Prevention Research

Volumn 4, Issue 4, 2011, Pages 592-607

  Park, Eun Jung ^a   Kondratyuk, Tamara P ^a   Morrell, Andrew ^b   Kiselev, Evgeny ^b   Conda Sheridan, Martin ^b   Cushman, Mark ^b   Ahn, Soyoun ^c   Choi, Yongsoo ^c   White, Jerry J ^c   Van Breemen, Richard B ^c   Pezzuto, John M ^a  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 6 (3 AMINOPROPYL) 5,6 DIHYDRO 5,11 DIOXO 11H INDENO[1,2 C]ISOQUINOLINE DIHYDROCHLORIDE; ALITRETINOIN; AM 6 36; ANTINEOPLASTIC AGENT; BEXAROTENE; CAMPTOTHECIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOOXYGENASE 2; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL STRAIN CACO 2; CELL STRAIN HL 60; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA MICROARRAY; DRUG ABSORPTION; DRUG DISTRIBUTION; FEMALE; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; LIVER MICROSOME; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION; HUMANS; INDENES; ISOQUINOLINES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RETINOID X RECEPTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955833958     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0004     Document Type: Article

References (52)

1. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990;345:224-9.
2. Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L. Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ 2004;11:S126-43.
3. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841-50. (Pubitemid 26006526)
4. Wolf G. Is 9-cis-retinoic acid the endogenous ligand for the retinoic acid-X receptor? Nutr Rev 2006;64:532-8.
5. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006;58:760-72.
6. Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 1994;54:4614-7. (Pubitemid 24276483)
7. Suh N, Lamph WW, Glasebrook AL, Grese TA, Palkowitz AD, Williams CR, et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 2002;8:3270-5. (Pubitemid 35155040)
8. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996;56:5566-70. (Pubitemid 26422151)
9. Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read 2004;14:236-8, 243-4, 251-3.
10. Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitart J. Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother 2006;7:907-15.
11. Morrell A, Placzek M, Parmley S, Grella B, Antony S, Pommier Y, et al. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors. J Med Chem 2007;50:4388-404. (Pubitemid 47378837)
12. Morrell A, Placzek M, Parmley S, Antony S, Dexheimer TS, Pommier Y, et al. Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J Med Chem 2007;50:4419-30. (Pubitemid 47378839)
13. Cushman M, Jayaraman M, Vroman JA, Fukunaga AK, Fox BM, Kohlhagen G, et al. Synthesis of new Indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J Med Chem 2000;43:3688-98.
14. Morrell A, Antony S, Kohlhagen G, Pommier Y, Cushman M. Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors. Bioorg Med Chem Lett 2006;16:1846-49.
15. Morrell A, Antony S, Kohlhagen G, Pommier Y, Cushman M. Systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor. J Med Chem 2006;49:7740-53. (Pubitemid 46033665)
16. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12. (Pubitemid 20213250)
17. Krishan A, Cabana R. Flow cytometric analysis of electronic nuclear volume and DNA content in normal mouse tissues. Cell Cycle 2004;3:380-3. (Pubitemid 41359090)
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9. (Pubitemid 17064313)
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8. (Pubitemid 34164012)
21. Guo J, Liu D, Nikolic D, Zhu D, Pezzuto JM, van Breemen RB. In vitro metabolism of isoliquiritigenin by human liver microsomes. Drug Metab Dispos 2008;36:461-8.
22. Li Y, Shin YG, Yu C, Kosmeder JW, Hirschelman WH, Pezzuto JM, et al. Increasing the throughput and productivity of Caco-2 cell permeability assays using liquid chromatography-mass spectrometry: application to resveratrol absorption and metabolism. Comb Chem High Throughput Screen 2003;6:757-67. (Pubitemid 38017483)
23. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res 2002;19:1907-14. (Pubitemid 36016041)
24. Lubet RA, Szabo E, Christov K, Bode AM, Ericson ME, Steele VE, et al. Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker studies. Mol Cancer Ther 2008;7:972-79. (Pubitemid 351551051)
25. Toma S, Isnardi L, Riccardi L, Bollag W. Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res 1998;18:935-42. (Pubitemid 28239619)
26. Wan H, Dawson MI, Hong WK, Lotan R. Overexpressed activated retinoid X receptors can mediate growth inhibitory effects of retinoids in human carcinoma cells. J Biol Chem 1998;273:26915-22. (Pubitemid 28471712)
27. Monden T, Kishi M, Hosoya T, Satoh T, Wondisford FE, Hollenberg AN, et al. p120 acts as a specific coactivator for 9-cis-retinoic acid receptor (RXR) on peroxisome proliferator-activated receptor-γ/RXR heterodimers. Mol Endocrinol 1999;13:1695-703. (Pubitemid 30645274)
28. Cushman M, Cheng L. Stereoselective oxidation by thionyl chloride leading to the indeno[1,2-c]isoquinoline system. J Org Chem 1978;43:3781-3.
29. Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multi-drug resistance. Cancer Res 2007;67:10397-405. (Pubitemid 350070815)
30. Antony S, Agama KK, Miao ZH, Hollingshead M , Holbeck SL , Wright MH , et al. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo- 11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol Pharmacol 2006;70:1109-20.
31. Kim SH, Oh SM, Song JH, Cho D, Le QM, Lee SH, et al. Indeno[1,2- c]isoquinolines as enhancing agents on all-trans retinoic acid-mediated differentiation of human myeloid leukemia cells. Bioorg Med Chem 2008;16:1125-32.
32. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810. (Pubitemid 47504871)
33. de Lera AR, Bourguet W, Altucci L, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 2007;6:811-20. (Pubitemid 47504872)
34. Muccio DD, Brouillette WJ, Alam M, Vaezi MF, Sani BP, Venepally P, et al. Conformationally defined 6-S-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity. J Med Chem 1996;39:3625-35.
35. Su J, Ciftci K. Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells. Int J Biochem Cell Biol 2002;34:950-7. (Pubitemid 34499593)
36. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-75. (Pubitemid 28015875)
37. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.
38. WAF1/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)/retinoid X receptor (RXR) heterodimer and RXR/RXR homodimer. J Biol Chem 2007;282:29987-97.
39. cdc2 involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res 1999;248:87-96.
40. Zhu H, Zhang L, Wu S, Teraishi F, Davis JJ, Jacob D, et al. Induction of S-phase arrest and p21 overexpression by a small molecule 2{[3-(2,3- dichlorophenoxy)propyl] amino}ethanol in correlation with activation of ERK. Oncogene 2004;23:4984-92. (Pubitemid 38938731)
41. cip1/waf1 and cell cycle distribution in carcinoid tumors. Cancer Invest 2002;20:348-56.
42. Yi YW, Kim D, Jung N, Hong SS, Lee HS, Bae I. Gadd45 family proteins are coactivators of nuclear hormone receptors. Biochem Biophys Res Commun 2000;272:193-8. (Pubitemid 30444921)
43. Cip1 in S phase. J Biol Chem 2003;278:25752-7.
44. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006;124:207-19. (Pubitemid 43069320)
45. Monte M, Benetti R, Collavin L, Marchionni L, Del Sal G, Schneider C. hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem 2004;279:11744-52. (Pubitemid 38401679)
46. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16. (Pubitemid 23346377)
47. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 2003;52:609-23. (Pubitemid 37034158)
48. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P, Moras D. Crystal. structure of the human RXRa ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J 2000;19:2592-601. (Pubitemid 30323548)
49. Freedman VH, Shin SI. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 1974;3:355-9.
50. Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993;14:1737-46. (Pubitemid 23290882)
51. Lamkin TJ, Chin V, Varvayanis S, Smith JL, Sramkoski RM, Jacobberger JW, et al. Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels. J Cell Biochem 2006;97:1328-38.
52. Yen A. Retinoic acid therapy served by ligands cross linking and masking CD38. Leuk Res 2007;31:423-5. (Pubitemid 46198936)